Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with RT and GDP in Early-stage NKTCL
NCT04511351Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT04511351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511351.